Home Cart Sign in  
Chemical Structure| 945976-43-2 Chemical Structure| 945976-43-2

Structure of LP-533401
CAS No.: 945976-43-2

Chemical Structure| 945976-43-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LP-533401 is an inhibitor of Tryptophan hydroxylase 1.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LP-533401

CAS No. :945976-43-2
Formula : C27H22F4N4O3
M.W : 526.49
SMILES Code : O=C(O)[C@@H](N)CC1=CC=C(C2=NC(N)=NC(OC(C3=CC=C(C4=CC=CC(F)=C4)C=C3)C(F)(F)F)=C2)C=C1
MDL No. :MFCD19053188
InChI Key :JZWUKILTKYJLCN-XEGCMXMBSA-N
Pubchem ID :44560455

Safety of LP-533401

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RIN-14B cells 2 μM 48 hours Inhibition of Tph1 function, alleviating hypoxia-induced oxidative stress Int J Mol Sci. 2019 Mar 18;20(6):1364

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced hepatic steatosis model Oral gavage 30 mg/kg Once daily for 12 weeks To evaluate the effect of LP-533401 on high-fat diet-induced hepatic steatosis. Results showed that LP-533401 reduced HFD-induced hepatic triglyceride accumulation. Diabetes Metab J. 2018 Jun;42(3):233-243
Sprague-Dawley rats High fat-sucrose diet-induced non-alcoholic steatohepatitis (NASH) model Gavage 17.5 mg/kg/day Once daily for 20 or 30 days To evaluate the effect of LP533401 on the progression of NASH. Results showed that LP533401 treatment significantly reduced 5-HT levels in serum and duodenum, and decreased hepatic lipid accumulation and inflammatory response. Front Pharmacol. 2020 May 14;11:553
Rats Chronic kidney disease model Oral gavage 30 and 100 mg/kg Once daily for eight weeks To investigate the effect of LP533401 on bone mineral status in rats with chronic kidney disease, finding that LP533401 treatment improved bone mineral status by modulating the kynurenic system in bone. Int J Mol Sci. 2020 Aug 19;21(17):5979
Rats (Rattus norvegicus albinus, Wistar) Ligature-induced periodontal disease model Gavage 25 mg/kg/d Once daily for 28 days To evaluate the effects of LP533401 in a rat periodontitis model on alveolar bone destruction and area of collagen. Results showed that LP533401 (25 mg/kg/d) for 28 d does not prevent bone loss and does not modulate host response in a rat model of induced periodontal disease. J Periodontal Res. 2016 Oct;51(5):661-8
Mice Hyperlipidemic mouse model induced by atherogenic diet Infusion 25 mg/kg bw 16 weeks (young mice) or 8 weeks (older mice) To evaluate the effects of LP533401 on skeletal bone mineral density (BMD) and aortic calcification in hyperlipidemic mice. Results showed that LP533401 blunted skeletal bone loss in lumbar vertebrae and the initial development of aortic calcification in young mice, but only increased lumbar BMD in older mice with limited effects on the progression of aortic calcification. Biochem Biophys Res Commun. 2024 May 28;710:149854

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.50mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories